RxDoctor Payments Data

Alan Micklin, MD

Cardiovascular Disease · Newark, DENPI 1477582518

Payments from drug & device makers

$538in general payments, 2019–2025

Across 28 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$100
  • Novartis$74
  • Boston Scientific$44
  • Abiomed$40
  • Johnson & Johnson$39
  • E.r. Squibb & Sons, L.L.C.$36
  • plus $206 from 10 others

What the payments were for

  • Food & beverage$538100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$538 in reported general payments places this provider in the 20th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$1,781,099
Medicare patients
4,463
Services billed
10,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban657$808,213
XareltoRivaroxaban221$274,304
EntrestoSacubitril/Valsartan86$125,643
Repatha SureclickEvolocumab53$40,270
Praluent PenAlirocumab52$30,726
JardianceEmpagliflozin14$17,327
Metoprolol Succinate789$12,775
Atorvastatin Calcium670$9,273
Ranolazine ErRanolazine42$6,990
Amlodipine Besylate392$3,989
Amiodarone Hcl121$3,777
Rosuvastatin Calcium213$3,727
Losartan Potassium282$3,499
Metoprolol Tartrate423$3,174
Diltiazem 24hr Er (Cd)Diltiazem Hcl55$3,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$808,213657 claims
Johnson & JohnsonXarelto$39$274,304221 claims
NovartisEntresto$74$125,64386 claims
Boehringer IngelheimJardiance$15$17,32714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →